CD39 Blockade Shows Potential in Early-Stage Lung Cancer

by | Apr 22, 2026 | Health

Spread the love
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments